



Appendix 4C – September 2018 Quarter

Brisbane, Australia 19th October 2018: Factor Therapeutics Limited (ASX: FTT), an Australian biotechnology company developing therapeutics for advanced wound care, has released its Appendix 4C (Quarterly Cashflow Statement) for the September 2018 Quarter.

Highlights:

- All patients in the Phase 2 clinical trial for venous leg ulcer healing have completed treatment
- Key parameters of a pilot study for diabetic foot ulcer have been defined, in association with US researchers
- Worldwide patent application filed for Ocular Wound Care technology
- Transaction Advisor appointed

The Company held cash reserves at the end of the quarter of \$4.047 million. Quarterly operating expenditure during the quarter was \$2.436 million, in line with forecasts, with \$1.705 million on direct R&D activities.

During the quarter, the Company announced that all patients had completed treatment in the Phase 2b study of VF001 in venous leg ulcers (VLU). Top-line results from the pivotal clinical trial are anticipated in mid-November 2018.

Also during the quarter the Company announced that, in association with US researchers, it had defined the key parameters of a pilot clinical study of VF001 for diabetic foot ulcer (DFU), with the aim of generating data to form the foundation of a Phase 2/3 clinical program in this indication.

The Company also announced that an international patent application (PCT) had been filed for its Ocular Wound Care technology, and that an application for Orphan Drug Designation in this indication was in preparation and expected to be submitted before the end of the year.

Subsequent to the end of the quarter, the Company announced that it had appointed Taylor Collison Limited as Transaction Advisor to assist with ongoing partnering discussions and advise on transactional options following a successful readout from the Phase 2 VLU clinical trial.

-ENDS-

Contact for Further Information:

Dr. Rosalind Wilson
Chief Executive Officer
Factor Therapeutics Limited
r.wilson@factor-therapeutics.com

About Factor Therapeutics

Factor Therapeutics Limited ("Factor") is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company's platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor's shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/3/00. Amended 30/9/01, 24/10/05, 17/12/10, 1/09/16

Name of entity

FACTOR THERAPEUTICS LIMITED

ABN

45 101 955 088

Quarter ended ("current quarter")

30-September-2018

Consolidated statement of cash flows

1. Cash flows from operating activities

	Current quarter \$A'000	Year to date (9 months) \$A'000
1.1 Receipts from customers	31	93
1.2 Payments for		
(a) research and development	(1,610)	(5,378)
(b) product manufacturing and operating costs	(95)	(352)
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(431)	(1,356)
(f) administration and corporate costs	(364)	(867)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	8	41
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	25	1,251
1.8 Other (provide details if material)	-	-
1.9 Net cash from/(used in) operating activities	(2,436)	(6,568)

2. Cash flows from investing activities

2.1 Payments to acquire:		
(a) property, plant and equipment	(2)	(5)
(b) businesses (see item 10)	-	-
(c) investments	-	-

Consolidated statement of cash flows		Current quarter	Year to date
		\$A'000	(9 months) \$A'000
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		-
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from/(used in) investing activities	(2)	(5)
3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares	-	4,172
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	(339)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from/(used in) financing activities	-	3,833
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	6,413	6,642
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,436)	(6,568)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(2)	(5)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	3,833

Consolidated statement of cash flows		Current quarter	Year to date
		\$A'000	(9 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	72	145
4.6	Cash and cash equivalents at end of quarter	4,047	4,047

5. Reconciliation of cash and cash equivalents	Current quarter	Previous quarter
at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	\$A'000	\$A'000
5.1 Bank Balances	2,501	2,549
5.2 Call deposits	1,546	3,864
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	4,047	6,413

6. Payments to directors of the entity and their associates	Current quarter
	\$A'000
6.1 Aggregate amount of payments to the parties included in item 1.2	(95)
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	
Payments to directors includes directors fees and executive directors salaries.	

7. Payments to related entities of the entity and their associates	Current quarter
	\$A'000
7.1 Aggregate amount of payments to the parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available

Add notes as necessary for an understanding of the position

- 8.1 Loan facilities
8.2 Credit standby arrangements
8.3 Other (please specify)

Total facility amount at quarter end \$A'000	Total drawn at quarter end \$A'000
-	-
-	-
-	-

- 8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

--

9. Estimated cash outflows for next quarter

- 9.1 Research and development
9.2 Product manufacturing and operating costs
9.3 Advertising and marketing
9.4 Leased assets
9.5 Staff costs
9.6 Administration and corporate costs
9.7 Other - Transaction costs related to issue of shares
9.8 **Total estimated cash outflows**

\$A'000
1,520
288
-
-
365
316
-
2,489

**10. Acquisitions and disposals of business entities
(items 2.1(b) and 2.2(b) above)**

- 10.1 Name of entity
10.2 Place of incorporation or registration
10.3 Consideration for acquisition or disposal
10.4 Total net assets
10.5 Nature of business

Acquisitions	Disposals
N/A	N/A

Compliance statement

¹ This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

² This statement gives a true and fair view of the matters disclosed.

Sign here: Original signed
(Company Secretary)



Date: 19-October-2018

Print name: Melanie Farris

Notes

- 1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- 2 If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.